Body Vision Medical Receives Regulatory Approval for LungVision® in India, Expanding Access to AI-Driven Advanced Imaging for Lung Cancer Diagnosis

WALTHAM, Mass., Sept. 16, 2025 /PRNewswire/ — Body Vision Medical, a global leader in AI-powered intraoperative imaging, is proud to announce that its LungVision AI-powered advanced imaging system has received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) in India. This approval marks a significant milestone in the company’s mission to improve early and accurate lung cancer diagnosis worldwide.

Lung cancer accounts for 8.1% of cancer-related deaths in India. Data from the National Cancer Registry Programme (NCRP) and GLOBOCAN project approximately 111,328 new cases will be diagnosed in 2025. Late diagnosis (75% of cases in stages 3–4) and limited access to specialized treatment contribute to a low five-year survival rate of about 15%, compared to 45% in developed countries.

“India market approval is a major step forward in our global mission to transform lung cancer care,” said Matt Baker, CEO at Body Vision Medical. “We are thrilled to partner with Assiz & Sarah Healthcare to make LungVision available in India, where there is a definitive need for earlier diagnosis of suspicious pulmonary nodules.”

LungVision, an AI-powered advanced imaging system that transforms any C-arm into a 3D imaging system, empowers physicians with real-time navigation and enhanced visualization to achieve more precise and accurate bronchoscopic biopsies. By enabling more confident diagnoses, LungVision supports the clinical goals of the NLCSP and has the potential to improve patient outcomes.

“We are excited to welcome Body Vision Medical’s technology to our portfolio, as it strengthens our commitment to advancing augmented lung and respiratory medicine through cutting-edge AI,” said Ravinder Saini, Director at Assiz & Sarah Healthcare. “Body Vision’s real-time imaging technology offers remarkable opportunities, significantly enhancing the chances for earlier cancer detection and ultimately improved lung cancer survival rates.”

For more information about LungVision and its availability in India, please visit Assiz & Sarah Healthcare (http://www.assizsarah.com).

About Body Vision Medical

Body Vision Medical believes in saving lives through the globalization of innovative medical technology. LungVision provides AI-powered real-time image guidance to address the clinical need for early, definitive lung cancer diagnosis and to enable effective treatment of lung lesions via minimally invasive procedures.

Visit bodyvisionmedical.com to learn more and connect with us on LinkedIn.

About Assiz & Sarah Healthcare

At Assiz & Sarah Healthcare, we forge strategic partnership to ensure access to cutting-edge solutions. We’re dedicated to transforming the way you experience healthcare. With our innovative technologies and compassionate care, we’re committed to improving lives and shaping a healthier future for all.

Contact:
Mike Hostetler
+1.651.366.9584
401171@email4pr.com

View original content:https://www.prnewswire.com/news-releases/body-vision-medical-receives-regulatory-approval-for-lungvision-in-india-expanding-access-to-ai-driven-advanced-imaging-for-lung-cancer-diagnosis-302556593.html

SOURCE Body Vision Medical